Phase 1 Endometrial Cancer Trial, Recruiting NCT07458347 Sponsor: Kestrel Therapeutics, Inc. Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 1 Endometrial Cancer Trial, Recruiting

NCT07458347
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years of age or older.
  • You must be willing and able to sign a consent form agreeing to take part in the trial.
  • You must have been diagnosed with a specific type of advanced cancer (such as non-small cell lung cancer, pancreatic cancer, colorectal cancer, or another solid tumor) that has spread or cannot be surgically removed, confirmed through a tissue sample.
  • Your cancer must have been tested and confirmed to have a specific gene change called a KRAS mutation before starting the trial.
  • Your cancer must have gotten worse during standard treatment, or you were unable to tolerate standard treatment.
  • You must be generally well enough to carry out daily activities with little or no limitation, as measured by a standard health score (confirm with trial site).
  • Your heart, blood, liver, and kidneys must be functioning well enough to meet the trial's requirements.
  • Your cancer must be measurable on scans at the start of the trial, according to standard measurement guidelines.

Who may not be able to join:

  • You have previously received or are currently receiving a treatment that targets the RAS or KRAS gene.
  • Your cancer has spread to the brain or spinal cord, or you have a tumor in the brain.
  • You are unable to swallow tablets or capsules taken by mouth.
  • You are pregnant, breastfeeding, or planning to become pregnant or father a child during the trial period.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 617-612-6810

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Kestrel Therapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
21 April 2026
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Participants With Dose-limiting Toxicities (DLTs) at the end of Cycle 1 (Each Cycle is 21 Days); Number of Participants With Treatment-emergent Adverse Events (TEAEs); Number of Participants With Treatment-related Adverse Events (TRAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov